AKT1 and prostate cancer: In the molecular perspective of CRPC type prostate cancer, alterations of components in the PI3K/Akt/mTOR signaling pathway have been reported in 42% of primary prostate tumors and 100% of metastatic tumors from biopsy specimens [8,9].